Defining mechanisms driving dry eye disease progression

定义驱动干眼病进展的机制

基本信息

项目摘要

PROJECT SUMMARY Aqueous-deficient dry eye is among the most common and debilitating clinical manifestations of systemic autoimmune diseases such as Sjögren's, lupus and rheumatoid arthritis. While it is well established that chronic inflammation of the ocular surface and exocrine glands (e.g., lacrimal gland) represents the predominant driving force in autoimmune-mediated dry eye disease, pathological alterations in the cornea are among the most common and debilitating clinical manifestations. With the cornea providing approximately two- thirds of the eye's focusing power and protecting the anterior eye from environmental, inflammatory and microbial insult, disease-mediated corruption of tissue function and homeostasis has a vast array of pathological outcomes. Indeed, a multitude of studies in both human patients and mouse models of aqueous- deficient dry eye illustrate late stage disease encompasses epithelial barrier disruption, epithelial hyperplasia, reduced corneal innervation and inflammatory cell infiltration. Thus, dry eye disease induces pathological changes along multiple levels. However, due to the limited understanding of the cellular makeup of the cornea, including the lineage relationships of specific cell types, the impact of dry eye on cell heterogeneity and lineage outcomes is unknown. To help solve this significant problem, we have begun to define the cellular diversity and differentiation trajectories of corneal cells and how these are perturbed by dry eye disease using single cell nuclei RNAsequencing in combination with the autoimmune regulatory (Aire)-deficient mouse model. Using this model, we have also begun to identify novel changes in corneal cell composition during the emergence of dry eye that may underlie disease development and progression. Based on these data we hypothesize that disease progression is promoted by an alteration in corneal cell fate that compromises the repair and cellular replenishment of the tissue. We propose to explore this hypothesis by first defining epithelial and stromal cell heterogeneity, differentiation trajectories and stem/progenitor cells in the homeostatic cornea. We will then seek to elucidate the mechanisms by which dry eye disease development impacts the self-renewal, differentiation capacity and function of corneal cells during dry eye disease development. Outcomes from these studies will aid in the development of therapeutics to halt disease progression, as well as the generation of diagnostic targets for early intervention.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sarah Monica Knox其他文献

Sarah Monica Knox的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sarah Monica Knox', 18)}}的其他基金

Lacritin Regulation of Homeostasis and Ocular Surface Health
泪泌素对体内平衡和眼表健康的调节
  • 批准号:
    10477335
  • 财政年份:
    2021
  • 资助金额:
    $ 39.77万
  • 项目类别:
Defining mechanisms driving dry eye disease progression
定义驱动干眼病进展的机制
  • 批准号:
    10290035
  • 财政年份:
    2021
  • 资助金额:
    $ 39.77万
  • 项目类别:
Lacritin Regulation of Homeostasis and Ocular Surface Health
泪泌素对体内平衡和眼表健康的调节
  • 批准号:
    10666529
  • 财政年份:
    2021
  • 资助金额:
    $ 39.77万
  • 项目类别:
Defining mechanisms driving dry eye disease progression
定义驱动干眼病进展的机制
  • 批准号:
    10661585
  • 财政年份:
    2021
  • 资助金额:
    $ 39.77万
  • 项目类别:
Lacritin Regulation of Homeostasis and Ocular Surface Health
泪泌素对体内平衡和眼表健康的调节
  • 批准号:
    10280641
  • 财政年份:
    2021
  • 资助金额:
    $ 39.77万
  • 项目类别:
Defining mechanisms driving salivary gland regeneration
定义驱动唾液腺再生的机制
  • 批准号:
    10063228
  • 财政年份:
    2019
  • 资助金额:
    $ 39.77万
  • 项目类别:
Defining mechanisms driving salivary gland regeneration
定义驱动唾液腺再生的机制
  • 批准号:
    9973214
  • 财政年份:
    2018
  • 资助金额:
    $ 39.77万
  • 项目类别:
Defining mechanisms driving salivary gland regeneration
定义驱动唾液腺再生的机制
  • 批准号:
    10437809
  • 财政年份:
    2018
  • 资助金额:
    $ 39.77万
  • 项目类别:
Defining mechanisms driving salivary gland regeneration
定义驱动唾液腺再生的机制
  • 批准号:
    10207600
  • 财政年份:
    2018
  • 资助金额:
    $ 39.77万
  • 项目类别:
Defining mechanisms driving salivary gland regeneration
定义驱动唾液腺再生的机制
  • 批准号:
    10655462
  • 财政年份:
    2018
  • 资助金额:
    $ 39.77万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 39.77万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 39.77万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 39.77万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 39.77万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 39.77万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 39.77万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 39.77万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 39.77万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 39.77万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 39.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了